Background-Endogenous adenosine can protect the overloaded heart against the development of hypertrophy and heart failure, but the contribution of A 1 receptors (A 1 R) and A 3 receptors (A 3 R) is not known. Methods and Results-To test the hypothesis that A 1 R and A 3 R can protect the heart against systolic overload, we exposed A 3 R gene-deficient (A 3 R knockout [KO]) mice and A 1 R KO mice to transverse aortic constriction (TAC). Contrary to our hypothesis, A 3 R KO attenuated 5-week TAC-induced left ventricular hypertrophy (ratio of ventricular mass/body weight increased to 7.6Ϯ0.3 mg/g in wild-type mice compared with 6.3Ϯ0.4 mg/g in KO mice), fibrosis, and dysfunction (left ventricular ejection fraction decreased to 43Ϯ2.5% and 55Ϯ4.2% in wild-type and KO mice, respectively). A 3 R KO also attenuated the TAC-induced increases of myocardial atrial natriuretic peptide and the oxidative stress markers 3Ј-nitrotyrosine and 4-hydroxynonenal. In contrast, A 1 R KO increased TAC-induced mortality but did not alter ventricular hypertrophy or dysfunction compared with wild-type mice. In mice in which extracellular adenosine production was impaired by CD73 KO, TAC caused greater hypertrophy and dysfunction and increased myocardial 3Ј-nitrotyrosine. In neonatal rat cardiomyocytes induced to hypertrophy with phenylephrine, the adenosine analogue 2-chloroadenosine reduced cell area, protein synthesis, atrial natriuretic peptide, and 3Ј-nitrotyrosine. Antagonism of A 3 R significantly potentiated the antihypertrophic effects of 2-chloroadenosine. Conclusions-Adenosine exerts protective effects on the overloaded heart, but the A 3 R acts counter to the protective effect of adenosine. The data suggest that selective attenuation of A 3 R activity might be a novel approach to treat pressure overload-induced left ventricular hypertrophy and dysfunction. (Circulation. 2008;118:1713-1721.) 
R ecently, we demonstrated that genetic deletion of CD73 (an ectonucleotidase that produces extracellular adenosine) exacerbated myocardial hypertrophy and heart failure resulting from left ventricular (LV) pressure overload produced by transverse aortic constriction (TAC), 1 suggesting that endogenous extracellular adenosine can protect against maladaptive hypertrophy. Adenosine exerts multiple functions through activation of individual adenosine receptor subtypes. 2-5 A 1 receptors (A 1 R) and A 3 receptors (A 3 R) are expressed in cardiomyocytes, and a substantial body of evidence indicates that adenosine can protect the heart during and after an ischemic insult. 6, 7 Liao et al 8 demonstrated that the adenosine analogue 2-chloroadenosine (CADO) also attenuated pressure overload-induced LV hypertrophy through activation of the A 1 R. Similar to A 1 R, the A 3 R are Gi protein-coupled receptors that have been shown to activate similar downstream signaling pathways. 9,10 A 3 R activation has also been reported to protect the heart against ischemic 11, 12 and doxorubicin-induced damage. 13 On the other hand, transgenic overexpression of the A 1 R 14 or A 3 R 15, 16 promotes cardiac dilation and dysfunction, suggesting that these receptors may also exert adverse effects on cardiac function. Although we and others have demonstrated that adenosine protects against LV hypertrophy and maladaptive remodeling during pressure overload, the distinct contributions of the A 1 R and A 3 R to this protective effect are not known. Here we examined the effect of A 1 R knockout (KO) mice and A 3 R KO mice on TAC-induced ventricular hypertrophy in vivo and extended our examination to the roles of A 1 R and A 3 R in modulating hypertrophy in cultured neonatal rat cardiomyocytes, free from hemodynamic and neurohormonal factors that can influence the in vivo heart.
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Methods Mice
Male C57BL/6 (Taconic, Germantown, NY) body weight-matched A 3 R KO mice 2 (crossed back to Taconic C57BL/6 mice at least 16 times), 8 to 12 weeks old, were used for TAC or control. A 1 R KO mice (129 background) and their control wild-type (WT) mice were generated as described previously. 17 The CD73 KO strain and control WT mice were generated as described previously. 1, 18 This study was approved by the Institutional Animal Care and Use Committee of University of Minnesota.
Minimally Invasive TAC Procedure
TAC of moderate (with the use of a 26-gauge needle to calibrate the degree of constriction) or severe (with the use of a 27-gauge needle) degree was created as described previously. 19 To ensure that similar pressure overload was produced in the KO and WT mice, the TAC procedure was performed on KO and corresponding WT mice on the same day by the same surgeon who was blinded regarding the genotype of the mice.
Echocardiography
Mice were anesthetized with 1.5% isoflurane. Echocardiographic images were obtained with a Visualsonics Veve 770 system as described previously. 19, 20 
Sample Collection and Western Blots
Myocardial samples for protein analysis were flash-frozen in liquid nitrogen, weighed on an electronic balance, and stored in liquid nitrogen until transfer into a Ϫ80°C freezer where they were maintained until analysis. Samples for histological analysis were fixed in formaldehyde. Protein expression was analyzed by Western blots as described previously 19 with the use of antibodies against atrial natriuretic peptide (ANP) (Peninsula Biolabs), 3-nitrotyrosine, 4-hydroxynonenal (Millipore), cyclooxygenase-2 (COX-2), c-Jun N-terminal kinase (JNK), phosphorylated JNK (p-JNK Thr183/Tyr185 ) (Santa Cruz Biotechnology, Santa Cruz, Calif), endothelial nitric oxide synthase (eNOS) (Transduction Laboratories), extracellular signal-regulated kinase (ERK), and p-ERK Thr202/Tyr204 , p-Akt Ser473 , and p-GSK-3␤ Ser21/9 (Cell Signaling Technology, Danvers, Mass).
Histological Staining and Measurement of Fibrosis
Tissue sections (6 m) from the central portion of the LV were stained with Sirius red (Sigma, St Louis, Mo) for fibrosis 19 and FITC-conjugated wheat germ agglutinin (AF488, Invitrogen, Carlsbad, Calif) to evaluate myocyte size. For mean myocyte size, the cross-sectional areas of at least 120 cells per sample and at least 4 samples per group were averaged.
Neonatal Rat Cardiomyocyte Isolation and Culture
Neonatal rat cardiomyocytes were isolated from 2-day-old Sprague-Dawley rats as described previously. 21 To induce hypertrophy, cells were treated with 50 mol/L phenylephrine for 48 hours. The stable adenosine analogue CADO (5 mol/L) was used to activate adenosine receptors (the affinities of CADO at rat A 1 R and A 3 R are 9.3 and 1890 nmol/L, respectively). 22 The selective inhibitors DPCPX and MRS1191 were used at 5 mol/L to block A 1 R and A 3 R, respectively. It has been reported that 5 mol/L MRS1911 selectively inhibits A 3 R activation without affecting A 1 R-dependent responses. 23 After treatment, cells were fixed with 4% paraformaldehyde and stained with rhodamine-conjugated phalloidin (5 U/mL in PBS, Invitrogen), DAPI, ANP (Peninsula Biolabs), and 3Ј-nitrotyrosine (Millipore), followed by Alexa Fluor 488 -or Alexa Fluor 633labeled secondary antibodies (Invitrogen). Protein synthesis was measured over 48 hours of treatment in 96 well plates by H 3phenylalanine incorporation.
Data Analysis
All values are expressed as meanϮSE. Kaplan-Meier survival analysis was performed with SigmaStat with the use of the Gehan-Breslow test. Two-way ANOVA was used to test for differences among treatment groups, followed by pairwise multiple comparisons of the Tukey test. Statistical significance was defined as PϽ0.05.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
A 3 R KO Attenuated LV Hypertrophy and Dysfunction Produced by Moderate Pressure Overload
LV structure and function were not different between A 3 R KO and WT mice under control conditions ( Figure 1A to 1G), and histological staining of LV tissue showed no difference in cardiac myocyte size or relative fibrosis between A 3 R KO and WT mice ( Figure 1C , 1D). After 5 weeks of moderate TAC (with the use of a 26-gauge needle to calibrate the degree of TAC), ventricular weight and the ratio of ventricular weight to body weight were significantly lower in the A 3 R KO mice than in WT mice ( Figure 1A , 1B), indicating that loss of A 3 R attenuated the TAC-induced myocardial hypertrophy. Histological staining showed that the A 3 R KO hearts had significantly less TAC-induced increases of LV fibrosis and myocyte hypertrophy ( Figure Echocardiographic imaging of the heart 5 weeks after TAC demonstrated significant increases of LV end-systolic diameter and LV end-diastolic diameter in both A 3 R KO and WT mice in comparison with mice of similar body weight without TAC ( Figure 1E, 1F ). However, TAC caused significantly less LV dysfunction in the A 3 R KO mice, as demonstrated by a higher ejection fraction and a smaller LV end-systolic diameter ( Figure 1E , 1G). Myocardial ANP (biochemical marker for LV dysfunction) was increased in both WT and A 3 R KO mice 5 weeks after TAC, but this increase was significantly less in the A 3 R KO mice ( Figure 2 ). These data indicate that the presence of the A 3 R exacerbated the LV hypertrophy and dysfunction in response to TAC.
Because recent studies using A 3 R KO mice demonstrated that attenuation of A 3 R signaling reduces the inflammatory response 2,24,25 in several pathological conditions, we examined myocardial tumor necrosis factor (TNF)-␣ and COX-2. TAC resulted in significant increases of TNF-␣ and COX-2 in the hearts of both WT mice and A 3 R KO mice ( Figure 2 ). However, the increase of COX-2 was significantly less in A 3 R KO mice than in WT mice. The TAC-induced increase of TNF-␣ tended to be less in the A 3 R KO mice (Pϭ0.10). In addition, hearts from WT mice had higher levels of 3Ј-nitrotyrosine and 4-hydroxynonenal after TAC than did A 3 R KO hearts, implying that the A 3 R KO mice had lower levels of oxidative stress ( Figure  2 ). eNOS uncoupling can be a source for increased oxidative stress, 19, 26 and we have found that the increase of myocardial eNOS protein after TAC was related to the degree of LV dysfunction. 19 Consistent with our previous report, myocardial eNOS protein was significantly increased in the WT mice after TAC, and this response was attenuated in the A 3 R KO mice ( Figure 2 ).
Activation of mitogen-activated protein kinases (MAPKs) and the phosphoinositide 3-kinase (PI3K) signaling pathway is often associated with increased oxidative stress 27, 28 and the development of LV hypertrophy or heart failure. 29 -31 To examine signaling pathways related to the protective effect observed in the A 3 R KO mice after TAC, total JNK and phosphorylated JNK, ERK, Akt, and GSK-3␤ were determined ( Figure 3 ). Under control conditions A 3 R KO had no effect on the myocardial content of total or phosphorylated ERK, JNK, Akt, or GSK-3␤. TAC caused significant increases of p-ERK Thr202/Tyr204 and p-JNK Thr183/Tyr185 and the ratio to their total proteins in both KO and WT mice. However, A 3 R KO significantly attenuated the TAC-induced increases of p-ERK Thr202/Tyr204 and p-JNK Thr183/Tyr185 (Figure 3 ), indicating that A 3 R KO attenuated the TAC-induced activation of the MAPK signaling pathways. In addition, the TAC-induced increases of p-Akt Ser473 and p-GSK-3␤ Ser21/9 were significantly attenuated in the A 3 R KO mice, suggesting decreased signaling through the PI3K-Akt pathway.
A 1 R KO Did Not Influence Ventricular Hypertrophy Produced by TAC but Exacerbated Mortality After Severe TAC
Although previous studies have demonstrated that either the adenosine analogue CADO 8, 32 or endogenous adenosine 1 can protect the heart from pressure overload-induced LV remodeling, the specific contribution of A 1 R activation has been controversial. 8, 32 To determine whether A 1 R KO might exacerbate the degree of hypertrophy and myocardial dysfunction later during systolic overload, we studied mice 4 weeks after moderate TAC (using a 26-gauge needle). This moderate systolic overload caused similar increases in the ratio of ventricular mass to body weight, LV end-diastolic diameter, LV end-systolic diameter, and LV wall thickness in A 1 R KO and WT mice ( Figure 4A to 4F). Moderate TAC of 4-week duration also caused similar decreases of LV ejection fraction in the 2 groups ( Figure 4C ). Although mortality tended to be higher in the A 1 R KO group during the 4 weeks after moderate TAC (5 of 17 mice died) compared with WT mice (2 of 17 WT mice died), this difference was not significant ( Figure 4H ).
Because mice with severe LV dysfunction are more likely to die after TAC, the relatively higher TAC-induced mortality in the A 1 R KO mice than in the WT mice might potentially have influenced ventricular weights of the surviving mice, that is, if the sicker A 1 R KO mice died early after TAC, the residual surviving animals might underestimate the overall response to systolic overload. Because the TAC-induced death occurred predominantly during the first 2 days after TAC, we determined the degree of hypertrophy 2 days after severe TAC when comparable numbers of A 1 R KO and WT mice survived. Compared with sham surgery, at 2 days after severe TAC the ratio of ventricular weight to body weight was similarly increased in WT (21Ϯ2.5%) and A 1 R KO mice (22Ϯ3.5%), indicating that A 1 R KO did not alter the acute hypertrophic response to severe pressure overload ( Figure III in the online-only Data Supplement). Taken together, the data indicate that A 1 R KO had no significant influence on TACinduced ventricular hypertrophy or dysfunction.
Because the A 1 R KO mice tended to have a higher mortality than their WT controls in this initial study, we subsequently examined whether this trend toward a higher mortality would be statistically significant when a more severe degree of systolic overload (using a 27-gauge needle) was applied. When TAC of severe degree was applied, the excess mortality in the A 1 R KO animals did in fact become Taken together, the data indicate that A 1 R KO had no significant influence on TAC-induced ventricular hypertrophy or dysfunction but resulted in significantly greater mortality in mice subjected to severe TAC.
CD73 KO Exacerbated Oxidative Stress and Hypertrophy Produced by Moderate Pressure Overload
The reduction of extracellular adenosine production produced by CD73 KO significantly exacerbated the hypertrophy ( Figure 5A , 5B), fibrosis ( Figure 5D , 5E), myocyte To validate these findings, we examined the ability of the adenosine analogue CADO to rescue the increased ventricular hypertrophy produced by TAC in the CD73 KO mice. We found that CADO attenuated the myocardial hypertrophy produced by moderate TAC of 2-week duration in the CD73 KO mice ( Figure VIII in the online-only Data Supplement).
The A 3 R Antagonist MRS1911 Potentiates the Antihypertrophic Effect of CADO in Neonatal Cardiomyocytes
Understanding the role of A 1 R and A 3 R in the response of the cardiomyocytes to systolic overload in vivo may be complicated by effects of adenosine on blood flow, neurohormonal responses, and inflammatory or paracrine responses. Therefore, we sought to determine the role of A 1 R and A 3 R in isolated cardiomyocytes in the setting of saturating levels of the nonselective adenosine analogue CADO. We previously demonstrated that CADO or adenosine reduced phenylephrine-induced hypertrophy and ANP expression in neonatal cardiomyocytes. 1 To examine the role of A 1 R and A 3 R in mediating antihypertrophic effects of CADO, we treated cells with 50 mol/L phenylephrine and 5 mol/L CADO in the presence or absence of selective A 1 R and A 3 R antagonists and then measured cell area, protein synthesis, and the oxidative stress marker 3Ј-nitrotyrosine. Phenylephrine increased cardiomyocyte protein synthesis ( Figure 6A, 6E) , cell area ( Figure 6B ), ANP expression ( Figure 6C) , and 3Јnitrotyrosine production ( Figure 6D , 6E) over 48 hours of treatment, whereas CADO significantly attenuated the phenylephrine-induced increases in these variables. Blocking A 1 R with DPCPX slightly reversed the CADO-induced reductions of cell area ( Figure 6B ) and ANP levels ( Figure 6C ) in the phenylephrine-treated cells. Inhibition of A 1 R caused a substantial increase in 3Ј-nitrotyrosine ( Figure 6D ), suggesting a role for A 1 R in modulating oxidative stress in the hypertrophying myocytes. Inhibition of the A 3 R with MRS1191 reduced protein synthesis, ANP expression, and 3Јnitrotyrosine production beyond the reduction caused by CADO alone (Figure 6 ). The reduction in 3Ј-nitrotyrosine by MRS1191 was confirmed by Western blot analysis (data not shown). The reduction in hypertrophy by the A 3 R antagonist was associated with reduced sustained activation of the MAPKs ERK and JNK ( Figure IX in the online-only Data Supplement). These results suggest that A 3 R contributes to increased oxidative stress, higher sustained activation of ERK and JNK, and an increased hypertrophic response to phenylephrine.
Discussion
To the best of our knowledge, this is the first report assessing the effect of A 1 R KO and A 3 R KO on chronic pressure overload-induced ventricular hypertrophy and contractile function. The major new finding is that A 3 R KO attenuated TAC-induced LV hypertrophy, fibrosis, oxidative stress, and dysfunction. Because adenosine has been reported to be cardioprotective in the setting of chronic pressure overload, 1, 8 the finding that disruption of A 3 R attenuated the TACinduced ventricular hypertrophy and dysfunction is unexpected and intriguing. Our finding that the A 3 R antagonist MRS1191 augmented the antihypertrophic effect of CADO in phenylephrine-treated isolated cardiomyocytes is in agreement with the concept that selective A 3 R blockade can enhance the beneficial effect of adenosine. These results support the novel concept that the adenosine A 3 R exerts adverse effects in the pressure-overloaded heart and suggest that A 3 R blockade may have potential to protect the heart against pressure overload-induced oxidative stress, LV remodeling, and contractile dysfunction.
The effect of the A 1 R on LV remodeling is controversial. CADO has been reported to attenuate TAC-induced LV hypertrophy in mice through A 1 R activation. 8 Furthermore, an A 1 R antagonist was reported to attenuate the antihypertrophic effect of CADO in vitro. 33 However, a subsequent study from the same group reported that A 1 R blockade had no effect on infarct-induced cardiomyocyte hypertrophy or LV remodeling in rats. 32 We have observed that moderate A 1 R overexpression in mice failed to exert a beneficial effect on myocardial infarct-induced ventricular remodeling (Y. Chen, PhD, unpublished data, 2007) . It is unclear why A 1 R blockade would attenuate the antihypertrophic effect of CADO, whereas A 1 R KO had no effect on TAC-induced hypertrophy. Nevertheless, the present finding that A 1 R KO exacerbated the death rate in mice exposed to severe TAC demonstrates that activation of the A 1 R can exert some degree of cardioprotection in the pressure-overloaded heart.
Although no previous reports have directly examined the effect of A 3 R KO on systolic overload-induced ventricular remodeling, there is evidence that A 3 R signaling can affect cardiac structure and function. Thus, transgenic mice with cardiac-specific overexpression of A 3 R developed a dilated cardiomyopathy characterized by increased ventricular mass, LV dilation, expression of biomarkers of hypertrophy, bradycardia, and systolic dysfunction, 15, 16 suggesting that chronically augmented A 3 R signaling in the heart is detrimental.
The MAPK and PI3K signaling pathways are often activated in response to extracellular stresses such as inflammation or oxidative stress 28 and have been shown to contribute to cardiac hypertrophy and heart failure. The increased myocardial oxidative stress after TAC in the present study, associated with activating phosphorylations of p-Akt Ser473 , p-ERK Thr202/Tyr204 , and p-JNK Thr183/Tyr185 and inactivating phosphorylation of GSK3␤ Ser21/9 , is consistent with previous reports. 19, 34 The decreases in TAC-induced oxidative stress, p-ERK Thr202/Tyr204 , p-JNK Thr183/Tyr185 , p-Akt Ser473 , and p-GSK3␤ Ser21/9 as a result of A 3 R KO likely contributed to the lesser degrees of fibrosis and cardiac myocyte hypertrophy in the A 3 R KO mice. TAC-induced ventricular hypertrophy is associated with increased eNOS expression 19 and eNOS uncoupling, 26 so that attenuation of the increase of eNOS in the A 3 R KO mice after TAC may have contributed to the decreased oxidative stress in this strain.
The effect of A 3 R on activation of myocardial PI3K/Akt signaling pathways in vivo has not been reported previously. However, the A 3 R agonist 2-chloro-N 6 -(3-iodobenzyl)adenosine-5Ј-N-methylcarboxamide (Cl-IB-MECA) or adenosine dose-and time-dependently increased p-Akt Ser473 in cultured neonatal rat cardiomyocytes 9 and A375 human melanoma cells, 35 which is consistent with our finding that A 3 R KO attenuated the increase of myocardial p-Akt Ser473 and its downstream target p-GSK Ser21/9 after TAC. Similarly, previous studies have reported that the A 3 R agonist Cl-IB-MECA or adenosine can activate p-ERK Thr202/Tyr204 in cultured cardiomyocytes 36 and tumor cell lines, 37 whereas the increase of p-ERK Thr202/Tyr204 in response to A 3 R agonist is PI3K/Akt dependent. 10 The finding that A 3 R activation increased p-ERK Thr202/Tyr204 in cultured cell lines 37 is conceptually consistent with our finding that A 3 R KO attenuated the TACinduced increase of p-ERK Thr202/Tyr204 . The effect of A 3 R on p-JNK Thr183/Tyr185 has not been reported previously.
The mechanism by which A 3 R KO protected the heart against the LV hypertrophy and dysfunction produced by TAC is of considerable interest. A 3 R are expressed in both cardiac myocytes and inflammatory cells. Our data demonstrating that antagonism of the A 3 R further reduced oxidative stress and expression of ANP in CADO-treated cardiomyocytes indicates that the A 3 R can contribute to oxidative stress and the hypertrophic response independent of the paracrine effects or inflammatory response that occur in vivo. The decrease in nitrotyrosine production in the isolated cardio- myocytes was accompanied by decreases of ERK and JNK activation, similar to the reduced activation of these enzymes in A 3 R KO mice. These results are consistent with numerous reports associating oxidative stress with activation of MAPK signaling. 28, 38, 39 In addition to a direct role of A 3 R on cardiomyocyte hypertrophy and oxidative stress, the A 3 R has also been demonstrated to modulate the inflammatory response. Specifically, the A 3 R appears important for mast cell degranulation, 2 neutrophil chemotaxis, 40 and infiltration of inflammatory cells. 24, 25 It is possible that A 3 R-mediated augmentation of the inflammatory response to the pressure overload produced by TAC could have exacerbated LV hypertrophy and dysfunction. Guo et al 41 demonstrated that inflammatory cell accumulation and infarct area were decreased in A 3 R KO mice compared with WT mice 24 hours after ischemia/ reperfusion injury, suggesting that the A 3 R can promote an increased inflammatory response in the heart. Our finding that A 3 R KO attenuated the TAC-induced increase of COX-2 and tended to decrease TNF-␣ after TAC supports a role for the A 3 R in the TAC-induced myocardial inflammatory response.
The finding that A 3 R KO enhanced the antihypertrophic effect of the CADO in neonatal cardiomyocytes suggests the possibility of interactions between A 3 R and A 1 R. There is some previous support for such interactions. Thus, Norton et al 42 demonstrated that adenosine A 2a R antagonists enhanced A 1 R-induced antiadrenergic responses in the heart, whereas A 2a R agonists attenuated the antiadrenergic actions of A 1 R activation. Although these investigators did not find interaction between A 3 R activity and A 1 R-mediated antiadrenergic effects in the heart, interaction between A 1 R function and A 3 R has been demonstrated in the hippocampus, where A 3 R activation desensitized A 1 R-dependent inhibition of excitatory neurotransmission by adenosine. 43 Although examination of potential interactions between adenosine receptors was beyond the scope of the present report, this is clearly an area in need of further study.
Unfortunately, there are no highly potent and selective A 3 R antagonists available for mice. Therefore, a limitation of the present study is that the protective effect of A 3 R KO on the pressure-overloaded heart could not be further confirmed by selective A 3 R inhibition with pharmacological compounds in an in vivo model.
In summary, A 3 R KO had no effect on LV structure or function in the unstressed heart but significantly attenuated TAC-induced LV hypertrophy, fibrosis, and dysfunction. Deletion of A 3 R also attenuated the TAC-induced increases of ventricular oxidative stress, COX-2, and the phosphorylation of p-ERK Thr202/Tyr204 , p-JNK Thr183/Tyr185 , p-Akt Ser473 , and p-GSK-3␤ Ser21/9 , suggesting that A 3 R-mediated increases of oxidative stress and/or inflammation exacerbate detrimental ventricular remodeling by activation of the MAPK and PI3K-Akt pathways. A 3 R agonists are currently under development to treat tumors, 44 inflammation, 45 or cardiac injury. The present findings suggest that careful evaluation of the effect of selective A 3 R agonists on ventricular hypertrophy and dysfunction in the overloaded or diseased heart will be of importance.
